Cytochromes P450, drugs, and diseases.

[1]  L. Moore,et al.  St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Vane.  Inhibitors of prostaglandin, prostacyclin, and thromboxane synthesis. , 1978, Advances in prostaglandin and thromboxane research.

[3]  F. Guengerich,et al.  Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. , 1985, The Journal of biological chemistry.

[4]  W. Trager,et al.  Genetic association between sensitivity to warfarin and expression of CYP2C9*3. , 1997, Pharmacogenetics.

[5]  D. Kroetz,et al.  Cytochrome P450 pathways of arachidonic acid metabolism , 2002, Current opinion in lipidology.

[6]  L. Koymans,et al.  Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. , 1999, Microbiology.

[7]  M. Hetzel,et al.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer , 1984, Nature.

[8]  H. Bolt,et al.  Effect of rifampicin.treatment on the metabolism of oestradiol and 17α-ethinyloestradiol by human liver microsomes , 1975, European Journal of Clinical Pharmacology.

[9]  R. Smith.  The role of metabolism and disposition studies in the safety assessment of pharmaceuticals. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  C R Shaw,et al.  Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. , 1973, The New England journal of medicine.

[11]  F. Gonzalez,et al.  Study of P450 function using gene knockout and transgenic mice. , 2003, Archives of biochemistry and biophysics.

[12]  W. Miller,et al.  Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. , 1997, Molecular endocrinology.

[13]  Erik Eliasson,et al.  The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro , 2001, European Journal of Clinical Pharmacology.

[14]  F. Guengerich.  Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. , 1988, Cancer research.

[15]  G L Snyder,et al.  Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? , 2001, The Journal of biological chemistry.

[16]  M. Sarfarazi,et al.  Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. , 1997, Human molecular genetics.

[17]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[18]  F. Guengerich,et al.  Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. , 1991, Chemical research in toxicology.

[19]  F. Guengerich,et al.  Purification of human liver cytochrome P-450 and comparison to the enzyme isolated from rat liver. , 1980, Archives of biochemistry and biophysics.

[20]  R. Kanamaru,et al.  Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. , 1994, Pharmacogenetics.

[21]  Ulrich Klotz,et al.  Inhibition of Terfenadine Metabolism , 1994, Clinical pharmacokinetics.

[22]  M. J. Coon,et al.  Purified liver microsomal cytochrome P-450. Separation and characterization of multiple forms. , 1975, The Journal of biological chemistry.

[23]  P. Hopkins,et al.  Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 , 1999, Clinical pharmacology and therapeutics.

[24]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[25]  J. Miller,et al.  The metabolism of methylated aminoazo dyes. VI. Intracellular distribution and properties of the demethylase system. , 1957, Cancer research.

[26]  F. Guengerich,et al.  Cytochrome p450 enzymes in the generation of commercial products , 2002, Nature Reviews Drug Discovery.

[27]  M. Cronin,et al.  Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. , 2000, Journal of clinical psychopharmacology.

[28]  Slobodan Petar Rendic.  Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[29]  J. Idle,et al.  The Relative Contribution of Monoamine Oxidase and Cytochrome P450 Isozymes to the Metabolic Deamination of the Trace Amine Tryptamine , 2003, Journal of Pharmacology and Experimental Therapeutics.

[30]  D. Smith,et al.  Human cytochrome P450s: selectivity and measurement in vivo. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[31]  R. Tyndale,et al.  Nicotine metabolism defect reduces smoking , 1998, Nature.

[32]  T. Rebbeck.  Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4 , 1999 .

[33]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[34]  J. Falck,et al.  Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  M. Spitz,et al.  Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. , 1997, Carcinogenesis.

[36]  M. Hecker,et al.  On the mechanism of prostacyclin and thromboxane A2 biosynthesis. , 1989, The Journal of biological chemistry.

[37]  H. Klenk,et al.  Identification and functional characterization of eight CYP3A4 protein variants. , 2001, Pharmacogenetics.

[38]  T. Aoyama,et al.  Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. , 1991, Archives of biochemistry and biophysics.

[39]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[40]  G. Tucker,et al.  Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[41]  J. Goldstein,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.

[42]  A. Brodie.  Aromatase inhibition and its pharmacologic implications. , 1985, Biochemical pharmacology.

[43]  J. Idle,et al.  Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians , 1979, Clinical pharmacology and therapeutics.

[44]  S. Imaoka,et al.  CYP4B1 is a possible risk factor for bladder cancer in humans. , 2000, Biochemical and biophysical research communications.

[45]  Jun Yokota,et al.  Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[46]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M A Butler,et al.  Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[48]  J. Ward,et al.  Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Yamazaki,et al.  Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. , 1998, Chemical research in toxicology.

[50]  S. E. Rau,et al.  Grapefruit juice—terfenadine single‐dose interaction: Magnitude, mechanism, and relevance , 1997, Clinical pharmacology and therapeutics.

[51]  H. Yamazaki,et al.  Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[52]  P. Vineis,et al.  Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. , 1996, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[53]  J. Idle,et al.  Influence of oxidation polymorphism on phenformin kinetics and dynamics , 1983, Clinical pharmacology and therapeutics.

[54]  B. Krämer,et al.  Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. , 2002, Transplantation.

[55]  S. Higuchi,et al.  Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects , 1996 .

[56]  T. Shimada,et al.  Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. , 1989, Cancer research.

[57]  K. Shimokata,et al.  Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 1999, Journal of the National Cancer Institute.

[58]  W. Kirch,et al.  Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. , 2008, British journal of clinical pharmacology.

[59]  D W Nebert,et al.  The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. , 1989, Critical reviews in toxicology.

[60]  T. Shimada,et al.  Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. , 1991, Chemical research in toxicology.

[61]  T. Shimada,et al.  Specificity of 17β-oestradiol and benzo[α]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432 , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[62]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[63]  Jun-yan Hong,et al.  Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 2000, Cancer research.

[64]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[65]  N. Walker,et al.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Xinxin Ding,et al.  Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. , 2003, Annual review of pharmacology and toxicology.

[67]  D. Breimer.  Genetic polymorphisms in drug metabolism: clinical implications and consequences in ADME studies , 1994 .

[68]  D. Nelson.  Comparison of P450s from human and fugu: 420 million years of vertebrate P450 evolution. , 2003, Archives of biochemistry and biophysics.

[69]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[70]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[71]  H. Kutsumi,et al.  Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1‐week regimen of proton pump inhibitor, amoxicillin and clarithromycin , 2003, Alimentary pharmacology & therapeutics.

[72]  M. Ingelman-Sundberg,et al.  Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. , 1999, Biochemical and biophysical research communications.

[73]  H. Yamazaki,et al.  Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.

[74]  G. Gervasini,et al.  Tryptamine: a possible endogenous substrate for CYP2D6. , 1997, Pharmacogenetics.

[75]  T. Shimada,et al.  Activation of Amino-α-carboline, 2-Amino-1-methyl-6-phenylimidazo[4,5- b ]pyridine, and a Copper Phthalocyanine Cellulose Extract of Cigarette Smoke Condensate by Cytochrome P-450 Enzymes in Rat and Human Liver Microsomes , 1991 .

[76]  F. Guengerich,et al.  A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. , 2001, Cancer research.

[77]  F. Guengerich.  Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. , 1988, Molecular pharmacology.